natgillin/translations-raw huggingface dataset:
Melter assembly according to any of claims 8 to 9 in which the melter has at least one of the following features: 
Talionički sklop u skladu s bilo kojim od patentnih zahtjeva 8 do 9, naznačen time što talionik ima najmanje jednu od sljedećih značajki:
The process of paragraph 26, wherein said acid catalyst is selected from the group consisting of mineral and organic acids. 
Postupak u skladu s patentnim zahtjevom 26, naznačen time što navedeni kiselinski katalizator se bira iz skupine koju čine mineralne i organske kiseline.
Arrangement according to Claim 4, in which the said module (30) for determining a frequency offset of an analogue communication signal comprises a low-pass filter (52) for narrow-band filtering around the continuous component of the demodulated signal. 
Raspored prema zahijevu 4, naznačen time, da spomenuti modul (30) za određivanje odlazne frekvencije analognog komunikacijskog signala sadrži duboko prolazni filter (52) za uskotračno filtriranje oko kontinuiranih sastavnih dijelova demoduliranog signala.
The method of claim 6, wherein the gain smoothing is enabled in response to a first LSP evolution rate associated with the frame being less than a threshold and a second LSP evolution rate associated with the frame being less than another threshold, and wherein the first LSP evolution rate corresponds to a slower adaptation rate than the second LSP evolution rate. 
Postupak prema zahtjevu 12, gdje je omogućeno ujednačavanje pojačanja kao odgovor na to da je prva brzina evolucije LSP parova pridružena sklopu manja od četvrtog praga 1 da je druga brzina evolucije LSP parova pridružena sklopu manja od petog praga, i gdje prva brzina evolucije LSP parova odgovara sporijoj brzini prilagođavanja u odnosu na drugu brzinu evolucije LSP parova.
The composition as claimed in claim 1, wherein after the extraction with alcohol, or water-alcohol solvent, the extract of Cynara scolymus is obtained by fractionation on a resin. 
Pripravci kako su navedeni u patentnim zahtjevima 1, 2 ili 3, naznačeni time da je ekstrakt Cynura scolymus dobiven ekstrakcijom vanjskih dijelova biljke alkoholom ili vodenim alkoholom kao otapalom te frakcioniranjem na smoli.
The method of claim 1, wherein the metabolic modulator is selected from the group consisting of polar aprotic solvents, DMSO, Acetone, N,N-Dimethylformamide and Acetonitrile. 
Postupak prema zahtjevu 10, naznačen time da je metabolički modulator odabran iz skupine koja sadrži polarna aprotička otapala, DMSO, aceton, N,N-dimetilformamid, i acetonitril.
Similarly, methods for separating the trans-(−)-A9-THC and the trans-(+)-A9-THC from the alcoholic-caustic phase, and methods for forming the first composition comprising (i) the 
(a) formiranje bifaznog sastava koji sadrži (i) prvu organsku fazu, i (ii) alkoholno-kaustičnu fazu koja sadrži trans- (+)-A?tetrahidrokanabinol;
The compound of claim 1 which compound is 3-(5-amino-4-benzoyl-pyrazol-1-yl)-N-cyclopropyl-4-methyl-benzamide, or a pharmaceutically acceptable salt thereof. 
Spoj formule I, naznačen time, da je to spoj 3-(5-amino-4-benzoil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid, ili njegov farmaceutski prihvatljiv derivat određen u zahtjevu 1, te da je za uporabu prema zahtjevu 1.
in the polymorph I form which shows in the X-ray diffractometry peak maxima of the 2 theta angle of 4.4, 14.8 and 20.5, comprising heating a compound of formula (I) in the polymorph II form from 195° C. to 222° C. at a heating rate of 10° C. to 30° C. per minute and subsequently cooling to 10° C. to 30° C. at a cooling rate of from 1 to 4° C. per minute. 
Postupak za dobivanje spoja formule (I) u polimorfu I kako je navedeno u zahtjevu 1, 2, 3, 4, ili 5, naznačen time da spoj formule (1) u polimorfu II kako je navedeno u zahtjevu 6 se zagrijava na od 195 do 222*C uz brzinu zagrijavanja od 10 do 30%C u minuti i naknadno se hladi na od 10 do 30*C uz brzinu hlađenja od 1 to 4%C u minuti.
The monoclonal antibody according to any one of the preceding claims wherein the antibody is competitively inhibited in its binding to human LIF by the monoclonal antibody produced by a hybridoma deposited on April 1st 2010 by Vall d'Hebron Institute of Oncology at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. 
Monoklonsko protutijelo ili njegov fragment, koji prepoznaju ljudski LIF pune duljine, no ne prepoznaju LIF fragment koji odgovara aminokiselinama od 1 do 160, naznačeni time što protutijelo proizvodi hibridomna stanična linija DSM ACC3054, deponirana 1. travnja 2010., od strane Onkološkog instituta Vall d’Hebron kod Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.
An enteric-coated tablet containing 20 mg of active compound was prepared from the following ingredients: 
Izvana obložena tableta koja sadrži 20 mg aktivnog spoja dobivena je iz slijedećih komponenti:
■ Ar1 represents an Aryl group optionally substituted, preferably substituted, by 1 up to 5 R group(s), wherein, each R, identical or different, is selected from the group consisting in Halogen atom, -Alkyl, -OAlkyl, ■ Y1 represents an -Alkyl- chain or a -S-Alkyl- chain; ■ m is 0 or 1; 
Po mogućnosti, u općoj formuli (II): m Arl predstavlja Arilnu skupinu izborno supstituiranu, po mogućnosti supstituiranu, s 1 do 5 R skupina, gdje, svakog R, istog ili različitog, se bira iz skupine koju čine Halogeni atom, -Alk1l, -OAlkil, m Y1 predstavlja lanac ili lanac; mje 0ili 1;
The characteristics of the foam thus obtained have been recorded on Table 1 in comparison with the foams prepared from resins of prior art. 
Karakteristike dobijene pjene navedene su u tabeli 1 u komparaciji sa pjenama, pripremijenim iz poznatih smola. HR P940799 B1 TABELA |
R is hydrogen, C1-7-alkyl, phenyl or benzyl; is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; 
R je vodik, C1−7−alkil, fenil ili benzil; je fenil ili piridinil, pri čemu atom dušika u piridinilskoj skupini može zauzimati različite položaje;
A method of treatment and/or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, kidney failure, thromboembolic disorders and arteriosclerosis comprising administering an effective amount of a pharmaceutical composition comprising a compound of formula (I): 
Lijek prema zahtjevu 18 ili 19 naznačen time da je za liječenje i/ili profilaksu zatajenja srca, angine pektoris, hipertenzije, plućne hipertenzije, ishemija, vaskularnih poremećaja, zatajenja bubrega, tromboembolijskih poremećaja i arterioskleroze.
In this case, in order to loosen the developer compacted by the suction through the discharge opening 3a or in order to discharge the developer by the discharging, the internal pressure (peak values of the negative pressure, positive pressure) of the developer accommodating portion has to be increased by increasing the amount of the volume change of the pump portion 2b. 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevom 1, naznačen time što navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje nastalu vrtnjom navedenog zupčanika (2a) u silu za rad navedenog crpnog dijela kako bi se promijenilo djelovanje navedenog crpnog dijela (2b).
The following paragraphs describe the operation of the system of the present invention. 
Sljedeći odjeljci opisuju rad sustava predmetnog izuma.
Ra and Rb together are (CH2)n where n is 3 or 4, to form, with the pyrimidine ring carbon atoms to which they are attached, a fused 5-or 6-membered carbocyclic ring; and 
Ride zajedno su (CH>),, pritom n je 3 ili 4, da bi formirali, s ugljikovim atomima pirimidinskog prstena za koji su vezani, kondenzirani 5-ili 6-člani karbociklički prsten; i
The initial treatment for hypercholesterolemia is often a diet low in fat and cholesterol coupled with appropriate physical exercise. 
Početno liječenje hiperkolesterolemije obično je ishrana s malo masti i kolesterola, uz odgovarajuću fizičku aktivnost.
wherein R1a is a halogen atom, a lower alkyl group, or a lower alkoxy group, and R2a and R3a are hydrogen atoms; and Ring B is wherein R4a is a phenyl group optionally substituted by a substituent selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a lower alkoxy group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group, and R5a is a hydrogen atom; and 
spoj formule (I) gdje je prsten A gdje je R1a atom halogena, niža alkil grupa, ili niža alkoksi grupa, i R2a i R3a su atomi vodika; i prsten B je gdje je R4a fenil grupa opcionalno zamijenjena sa supstituentom izabranim iz grupe koju čine atom halogena, cijano grupa, niža alkil grupa, halo-niža alkil grupa, niža alkoksi grupa, halo-niža alkoksi grupa, mono-ili di-niža alkilamino grupa, karbamoil grupa, i mono-ili di-niža alkilkarbamoil grupa; ili heterociklil grupa opcionalno zamijenjena sa atomom halogena, cijano grupa, niža alkil grupa, niža alkoksi grupa, karbamoil grupa, ili mono-ili di-niža alkilkarbamoil grupa, i R5a je atom vodika; i Y je -CH2-; ili njegova farmaceutski prihvatljiva sol;
A method according to any preceding claim wherein the compound of formula (III) is formed by a method comprising forming a compound of formula (IIIa): wherein: 
Postupak sukladno bilo kojem od prethodnih zahtjeva, naznačen time što se spoj formule (III) stvara postupkom koji sadrži reakciju spoja formule (II) sa spojem formule (VIII):
The chemically modified glycosaminoglycan according to any one of claims 1-4, wherein the glycosaminoglycan that is modified is heparin. 
5. < Kemijski modificirani glikozaminoglikan prema bilo kojem od zahtjeva 1-4, naznačen time da glikozaminoglikan koji je modificiran je heparin.
wherein Hc is selected from the group of tetrahydropyranyl, tetrahydrofuranyl, piperidinyl and pyrrolidinyl; 
Hc je odabran iz skupine koju čine: tetrahidropiranil, tetrahidrofuranil, piperidinil, pirolidinil;
Assay Buffer used throughout the assay: 50mM HEPES, 10mM MgCl2, 0.125mg/ml BSA, pH adjusted to 7.4 with KOH. hOT-CHO membranes were prepared at a concentration of 0.3mg protein/ml in assay buffer. 
U ovom ispitivanju upotrebljavan je ovaj Pufer za ispitivanje: 50 mM HEPES, 10 mM MgCh, 0,125 mg/ml BSA, a pH je s KOH podešen do 7,4. hOT-CHO membrane preparirane su u koncentraciji od 0,3 mg protein/ml u puferu za ispitivanje.
(c9) an antigen-binding site comprising an L chain variable region amino acid sequence of SEQ ID NO: 64 (L chain variable region of L408); and 
(C9) mjesto vezanja antigena koje obuhvaća aminokiselinsku sekvencu varijabilnog područja L-lanca od SEQ ID NO: 64 (varijabilno područje L- lanca od L408); i
Cup as claimed in one of the preceding claims, characterized in that the predetermined breaking line (5) of the wall section (4) comprises a perforated part. 
Spremnik (1) prema jednom od prethodnih patentnih zahtjeva, naznačen time da je unaprijed određena linija loma (5) dijela stijenke (4) u osnovi oblikovana kao perforacija.
The polymeric device material of claim 1 wherein the amount of monomer [2] is 0.5 to 3% (w/w). 
Polimerni materijal za navedeni uređaj u skladu s patentnim zahtjevom 1, naznačen time što količina hidrofilnog pobočnog makromera je 1 do 10 % (težinski).
The method of claim 1, wherein the first selected component includes at least one of hard plastic, soft plastic and mixed plastic. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da prva odabrana komponenta sadržava najmanje jedan tvrdi plastični materijal, jedan meki plastični materijal 1 jednu mješavinu plastičnih materijala.
Said guiding members may be positioned in the corners of the inner part, so that they also provide a reinforcement of the corners of the packaging. 
Navedeni članovi za vođenje mogu biti postavljeni na uglovima unutarnjeg dijela, tako da mogu također osigurati i pojačanje uglova pakiranja.
contacting a G protein-coupled receptor with an optionally labelled known ligand to the receptor in the presence or absence of a test compounds, wherein said G protein coupled receptor comprises an amino acid sequence selected from the group consisting of: 
(a) stavljanje u kontakt G protein-kupiranog receptora sa po izboru označenim poznatim ligandom za receptor u prisutnosti ili odsutnosti test spojeva, pri čemu navedeni G protein kupirani receptor obuhvaća aminokiselinsku sekvencu izabranu iz skupine koju čine:
a chelating compound in the range from about 0.1 to 0.01 % w/w; 
kelatnog spoja u rasponu od 0,1 do 0,01 % wt/wt;
The method according to claim 1, wherein said cell concentration in the suspension is between 0.5 and 4×106/mL. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu je koncentracija navedenih stanica u kulturi sadržana između 0.5 i 4 x 10%/mL ili je najmanje 4 x 105/mL.
This substrate may be provided with an optional axial passageway. 
Ovaj supstrat 30 može biti osiguran sa opcijskim aksijalnim prolazom 32, kao što je prikazano na SI. 2.
The wedge part connection 46 should preferably be designed such that it breaks when the wedge part 45 is pressed into the recess 43 formed in the main tongue body. 
Komplet podnih ploča prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da glavno tijelo jezika sadrži spoj klinastog dijela (46) koji se nalazi u udubljenju (43).
The Ang2-binding molecule according to claim 1, wherein said immunoglobulin single variable domain is a VHH. 
Ang2-vezujuća molekula u skladu sa zahtjevom 1, naznačena time, da navedena jednostruka varijabilna domena imunoglobulina je VHH.
Milling machine according to claim 1, characterized in that a drive rotation as well as a milling rotation and a forward feed motion are producible by means of wheel hub motors. 
Glodalica (100, 100a-100e) prema jednom od prethodnih zahtjeva 1-7, naznačena time, da se pogonska rotacija (AR, AR1), kao i rotacija glodalica (FR, FR1) i pomicanje prema naprijed (VB1-VB4) mogu se generirati motorima na glavčini kotača.
A compound for use according to claim 14, wherein the disease or condition is selected from pulmonary hypertension, erectile dysfunction, hypertension, atherosclerosis, renal disease, asthma, T-cell dysfunction, ischemia reperfusion injury, neurodegenerative diseases, wound healing, and fibrotic diseases. 
Spoj za uporabu prema zahtjevu 14, naznačen time da je bolest ili stanje izabrano iz plućne hipertenzije, erektilne disfunkcije, hipertenzije, ateroskleroze,
A method for treating a Hepatitis B virus infection in a patient comprising administering an effective amount of alisporivir and optionally administering to the patient an interferon or a direct antiviral agent. 
Alisporivir za uporabu prema zahtjevu 1, naznačen time, da se pacijentu primjenjuje učinkovita količina alisporivira i opcijski se daje interferon ili direktno antivirusno sredstvo.
A pharmaceutical composition used for treatment and/or prevention of cancer comprising the RNAi molecule according to any of [1] to [4] and/or the vector according to [5] in combination with a 5-FU antitumor agent. 
Farmaceutski sastav, naznačen time, da obuhvaća RNKi-molekulu prema zahtjevu 1 ili zahtjevu 2, i/ili vektor prema zahtjevu 3, u kombinaciji s antitumorskim sredstvom 5-FU.
Adiponectin knockout mice are housed (7-9 mice/cage) under standard laboratory conditions at 22°C and 50% relative humidity. 
Adiponektin onesposobljeni miševi su smješteni (7-9 miševa/kavez) uz standardne labaratorijske uvjete pri 22*C i 50% relativne vlage.
about 10 minutes. 
€) u trajanju od oko 10 min.
contacting a peptide consisting of the candidate sequence selected in step (ii) with an antigen presenting cell; 
(ill) stavljanja u kontakt peptida koji se sastoji od slijeda kandidata odabranog u koraku (ii) sa stanicama koje predočavaju antigene;
The plurality of food items for the use of any one of the preceding claims, wherein each of the food items comprises a total of 0-6g fiber. 
Komplet iz jednog od patentnih zahtjeva 1-12, za uporabu u postupku pripreme pacijentovih crijeva i utrobe za medicinski postupak.
adding laminin onto collagen solution and mixing (112), 
dodavanja laminina u otopinu kolagena i miješanje (112),
fragrance in an amount of from about 2% to about 4% by weight of the total composition. 
miris u količini od 2% do 4 masenih% ukupnog pripravka
It is naturally also possible, instead, or in combination therewith, to provide several supplies, which also holds for the extraction. 
Umjesto toga, moguće je naravno također, ili u kombinaciji s tim, da se predvidi nekoliko dovoda, koji se također drže i za ekstrakciju.
the threonine at position 5 of the FG loop (SEQ ID NO: 75) is substituted to with an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W, and Y; 
treonin na položaju 5 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W te Y;
The method of producing hydroxyalkylcellulose microparticles according to claim 15 or 16, wherein a concentration of the hydroxyalkylcellulose aqueous solution is within a range from 1 to 5% by weight. 
Postupak proizvodnje mikročestica od hidroksipropilceluloze u skladu s patentnim zahtjevom 4 ili 5, naznačen time što je koncentracija vodene otopine hidroksipropilceluloze u rasponu od 1 do 5%, težinski.
A method according to claim 1 or 2, wherein said gene B is part of the genome of the cell. A method according to any one of claims 1 to 3, wherein the cell is co-transformed with at least two different genes A1 and A2 and optionally with at least two different genes B1 and B2. 
Metoda u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu se stanice nazivaju kotransformiranima s najmanje dvije različite varijante gena A za rekombinaciju, koji su geni A1 i A2, i neobavezno s najmanje dvije različite varijante gena B za rekombinaciju, koji su geni B1 i B2.
A compound of formula (I) or a physiologically acceptable solvate thereof for use in the treatment of patients according to claim 5, wherein the inflammatory and/or allergic condition is nasal polyps. 
Spoj formule (I), ili njegov fiziološki prihvatljiv solvat, u skladu s patentnim zahtjevom 13, naznačen time što je namijenjen upotrebi u liječenju pacijenata s polipima u nosu.
The composition according to claim 1, wherein component (A) is 3difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl) amide and component (B2) is selected from the group consisting of difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
optionally converting the compound of Formula 1 or a salt thereof into a pharmaceutically acceptable complex, salt, solvate or hydrate, wherein R1 and R2 in Formula 6 and in Formula 7 are as defined above in Formula 1. The compound of Formula 6, above, may be prepared by hydrolyzing a compound of Formula 3, 
, ili njegove soli, s kiselinom i vodom, kako bi se dobilo spoj Formule 1, ili njegovu sol; ili (b) izbornom prevođenju spoja Formule 1, ili njegove soli, u njegov farmaceutski prihvatljiv kompleks, sol, solvat 20 ili hidrat, gdje R' i R* u Formuli 2 su definirani kao za Formulu 1.
These auxiliary columns 31 may be integrated in the wall elements 2 or may be installed in the skeleton before the wall elements 2 is mounted to the skeleton. 
Pomoćni stupovi 31 mogu biti integrirani u zidne elemente 2 ili postavljeni u kostur prije nego se zidni elementi 2 postavljaju u kostur.
The pharmaceutical composition according to claim 1, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 12 h to 24 h following administration. 
Farmaceutski sastav za upotrebu prema patentnom zahtjevu 1, naznačen time da daje stacionarno stanje razina u plazmi 3 a-hidroksi-3B-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-ona u rasponu od 5 ng/ml do 500 ng/ml u trajanju od 12 sati do 24 sata nakon davanja.
the reaction of a compound of the formula (25): 
(97) Broj objave europskog patenta:
A pharmaceutical composition comprising a eutectic of 25%±2% mannitol and 75%±2% Cyclobenzaprine HCl by weight, wherein the mannitol is B-mannitol or δ-mannitol. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da obuhvaća eutektik od 75% ± 2% ciklobenzaprin-klorovodika i od 25% ± 2% manitola.
The system according to claim 18 wherein the fault detector is a header compression device that is provided between a switch and a data interface. 
Sustav temeljem zahtjeva 21, naznačen time da je uređaj za otkrivanje pogrešaka (8) uređaj za kompresiju podataka zaglavlja koji je postavljen između uređaja za prebacivanje (9) 1 podatkovnog sučelja (10).
or comprising a compound of any one of claims 1 to 6 or composition of claim 7 and a coagulant; 
ili obuhvaća tvar iz bilo kojeg od patentnih zahtjeva 1 do 6 ili sastav iz patentnog zahtjeva 7 i koagulans;
Modular antibody according to claim 6, wherein said antigen binding site specifically binds to Her2 and contains an amino acid sequence selected from the group consisting of SEQ.ID numbers as listed in Table 4 and 5, contained in an EF and/or AB and/or CD loop. 
Modularno protutijelo prema zahtjevu 6, naznačeno time, da se spomenuto mjesto vezanja antigena specifično veže na Her2 1 sadrži aminokiselinsku sekvencu odabranu iz skupine koja se sastoji od SEQ ID brojeva popisanih u Tablici 4 1 Tablici 5, te koja je u sastavu čvora EF i/ili čvora AB i/ili čvora CD.
The process of claim 1, wherein a ratio between the median particle size of the substantially water insoluble polymer particles and the median particle size of the water soluble and/or water swellable material particles is in a range of from 1:1.5 to 1:6. The process of claim 1, wherein the water soluble and/or water swellable material particles comprise from 0.1 wt% to 25 wt. %, or from 0.5 wt. % to 20 wt. % of the total weight of the core particles, the substantially water insoluble particles and water soluble and/or water swellable material particles in the mixing step. 
Postupak sukladno zahtjevu 1, naznačeno time, da je omjer između čestica srednje veličine znatno netopivih u vodi, polimernih čestica i materijalnih čestica srednje veličine topivih u vodi i bubre u istoj, u odnosu od 1:1.5 do Postupak sukladno zahtjevu 1, naznačeno time, da su topive materijalne čestice, koje takođe bubre u istoj, sadrže od 0.1 wt% do 25 wt. %, ili od 0.5 wt. % do 20 wt. % cijele težine osnovnih čestica, potpuno netopivih čestica i čestica topivih u vodi i bubre u istoj, kada se pomiješaju.
The combination, combination for use or immune checkpoint inhibitor for use of claim 21, wherein the cancer is selected from among pancreatic cancer, breast cancer, prostate cancer, bladder cancer, gastric cancer, mesothelioma, NSCLC, and colon cancer. 
Kombinacija, kombinacija za uporabu ili inhibitor imunološke kontrolne točke za uporabu prema zahtjevu 21, pri čemu je rak odabran od između raka gušterače, raka dojke, raka prostate, raka mjehura, raka želuca, mezotelioma, NSCLC 1 raka debelog crijeva.
In liquid pharmaceutical compositions of the present invention, pravastatin of compactin, in combination with any other solid excipients are dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin. 
U tekućim se farmaceutskim smjesama pravastatin ii kompaktin, u kombinaciji s bilo kojim drugim čvrstim pomoćnim tvarima, otapaju ili suspendiraju u tekućem nosaču kao što je voda, biljno ulje, alkohol, polietilen glikol, propilen glikol ili glicerin.
The solution was filled into 25 ml vials using an automatic pump and silicone platinum-cured tubing 3.2 mm. 
Otopina je napunjena u ampule od 25 ml primjenom automatske pumpe i cijevi pod tlakom obrađene silicijem i platinom 3.2 mm.